| ￥5800 | |
| Z04502-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | |
| Protein Construction |
|
|
| Purity | > 95% as determined by Bis-Tris PAGE | |
| Endotoxin Level | Less than 1EU per μg by the LAL method. | |
| Biological Activity | Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch. | |
| Expression System | E.coli | |
| Theoretical Molecular Weight | 18.2 kDa | |
| Apparent Molecular Weight | The protein has a predicted MW of 18.2 kDa same as Bis-Tris PAGE result. | |
| Formulation | Supplied as 0.22 μm filtered solution in 20 mM PB, 250 mM NaCl, 50 mM L-arginine (pH 7.4). | |
| Concentration | Verified by one or more methods from 0.64mg/ml A280/Bioactivity/BCA/Bradford. | |
| Storage & Stability | This product remains stable for 6 months at -80°C or below. Avoid repeated freeze-thaw cycles. |
| Target Background | Interleukin (IL)-18 was originally discovered as a factor that enhanced IFN-γ production from anti-CD3-stimulated Th1 cells, especially in the presence of IL-12. Upon stimulation with Ag plus IL-12, naïve T cells develop into IL-18 receptor (IL-18R) expressing Th1 cells, which increase IFN-γ production in response to IL-18 stimulation. |
| Synonyms | IL-18; IL18; IGIF; IL-1F4; IL-1 gamma; IL1F4; IL-1g; Interleukin 1; IL-1γ; IL-1 γ |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
